# Phase II Study of BI 2536 in Prostate Cancer

> **NCT00706498** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 20 (actual)

## Conditions studied

- Prostatic Neoplasms

## Interventions

- **DRUG:** BI 2536

## Key facts

- **NCT ID:** NCT00706498
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** 2008-02
- **Final completion:** —
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2014-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00706498

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00706498, "Phase II Study of BI 2536 in Prostate Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00706498. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*